Drug Profile


Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; SAVAYSA

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Embolism; Stroke; Venous thromboembolism
  • Registered Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism
  • Phase I Venous thrombosis

Most Recent Events

  • 06 Mar 2017 Phase-III clinical trials in Embolism (Prevention) and Stroke (Prevention) in Ukraine (PO)
  • 06 Mar 2017 Daiichi Sankyo and Chiltern International plans the phase III ENVISAGE-TAVI AF (EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation – Atrial Fibrillation) trial for Atrial Fibrillation in USA (NCT02943785)
  • 06 Mar 2017 Daiichi Sankyo initiates the phase IIIb ENTRUST-AF-PCI trial for Embolism (Prevention) and Stroke (Prevention) in Ireland, Netherlands, Lithuania, Austria, Hungary, Taiwan and Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top